Souvenaid Clinical Trial Programme

The scientific rationale behind the development of Souvenaid is based on the ability of specific nutrients to support neuronal membrane and synapse formation. Patients with Alzheimer’s disease have specific nutritional needs and it has been hypothesised that providing the right combination of nutrients may provide clinically relevant benefits in this population. Over 10 years of research have contributed to the development of Souvenaid – preclinical work conducted by scientists at the Massachusetts Institute of Technology (MIT) formed the foundation for our clinical trial programme

Preclinical studies

Pre-clinical research has demonstrated that specific combination of nutrients support synapse formation.

Read More

Souvenir I

Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. The results of Souvenir I were published in Alzheimer’s and Dementia in 2010.

Read More

Souvenir II

Efficacy of Souvenaid in mild Alzheimer’s disease: a randomized, controlled trial. The results of Souvenir II were published in the Journal of Alzheimer’s Disease in 2012.

Read More


Souvenaid® as an add-on intervention in patients with mild to moderate Alzheimer’s disease using Alzheimer’s disease medication: results from a randomized, controlled, double-blind study (S-Connect)

Read More


The LipiDiDiet study is currently ongoing – details of the study design were presented at the CTAD congress in 2011 Freund-Levi Y, et al. CTAD, San Diego, November 2011; J Nutr Health Aging (Nov suppl.)

Read More

Other Supporting Data

A summary of all recent clinical trials and papers on nutrition in Alzheimer’s disease and Souvenaid

Read More